Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies Inc (OSUR) is a leader in non-invasive diagnostic solutions and molecular testing systems for global healthcare markets. This comprehensive news hub provides investors and healthcare professionals with essential updates on corporate developments, regulatory milestones, and product innovations.
Access timely updates including earnings reports, FDA clearances, clinical trial results, and strategic partnerships. Our curated collection features press releases covering oral fluid diagnostics advancements, molecular testing solutions, and cryosurgical product developments – all critical for assessing the company's market position.
Key content categories include financial performance disclosures, manufacturing expansion announcements, research collaborations, and public health initiatives. The archive serves as a vital resource for tracking OSUR's contributions to HIV testing, substance abuse screening, and genetic material stabilization technologies.
Bookmark this page for streamlined monitoring of OraSure's operational updates and industry leadership in medical device innovation. Check regularly for authoritative information supporting informed analysis of this diagnostic technology pioneer.
OraSure Technologies (NASDAQ: OSUR) has announced it will release its first quarter 2025 financial results on May 7th, 2025 at 5 p.m. ET. The company will host an earnings conference call to discuss Q1 2025 results and business developments.
A webcast of the conference call will be accessible through OraSure's investor relations website. The webcast recording will remain available for approximately one year after the call. Participants wishing to ask questions during the call must pre-register through the provided registration link.
OraSure Technologies (NASDAQ: OSUR) has announced a significant stock repurchase program authorized by its Board of Directors. The program allows for the repurchase of up to $40 million of common stock over a 24-month period, to be funded from cash on hand.
The company, which specializes in point-of-need and home diagnostic tests and sample management solutions, will implement the repurchase through various methods in compliance with securities laws. Management retains discretion over the amount and timing of share repurchases, with the ability to modify, suspend, or discontinue the program without prior notice.
OraSure Technologies (NASDAQ: OSUR) reported Q4 2024 financial results showing total net revenues decreased 51% to $37.4 million from $75.9 million in Q4 2023, primarily due to declining COVID-19 revenues. Core revenues increased 10% year-over-year to $36.5 million, with Diagnostics revenues up 9% to $18.8 million and Sample Management Solutions up 14% to $14.8 million.
The company reported a GAAP operating loss of $12.4 million compared to operating income of $3.9 million in Q4 2023. Cash and cash equivalents stood at $267.8 million. Notable developments include the acquisition of Sherlock Biosciences to expand molecular diagnostics capabilities, FDA approval for expanded age range of OraQuick HIV Self-Test, and a $7.5 million BARDA contract for Marburg Virus Disease test development. The company guides Q1 2025 revenues between $27.5-31.5 million.
OraSure Technologies (NASDAQ: OSUR) has scheduled its Q4 2024 earnings conference call for February 25, 2025, at 5 p.m. ET. The company will discuss fourth quarter financial results and business developments during the call.
A webcast will be available on OraSure's investor relations website, with registration required at least 10 minutes before the call. The webcast recording will be accessible for approximately 90 days after the event. Participants who wish to ask questions during the call must pre-register through a provided link to receive access details.
OraSure Technologies (NASDAQ: OSUR), a leading provider of point-of-need and home diagnostic tests and sample management solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver their presentation on Thursday, January 16, 2025, at 9:00 a.m. PT.
Interested parties can access both a live webcast and replay of the presentation through the 'Events and Presentations' section of OraSure's investor relations website. This significant healthcare industry event provides OraSure an opportunity to showcase its developments and strategies to investors and healthcare professionals.
OraSure Technologies (NASDAQ: OSUR) announced FDA approval for expanding the age range of its OraQuick® HIV Self-Test to include individuals 14 years and older, down from the previous minimum age of 17. This expansion addresses a critical need, as CDC data shows that 19% of new HIV diagnoses in the US occur among those aged 13-24, with only 6% of high school students ever being tested for HIV. Almost half of young people with HIV are unaware of their status.
The OraQuick® HIV Self-Test has been available to US consumers since 2012. The test includes educational materials and care information to help users make informed decisions regardless of results. This approval aims to increase HIV testing accessibility among adolescents and support early connection to care for those testing positive.
OraSure Technologies announced the expansion of its OraQuick® HIV Self-Test approved age range to include individuals 14 years and older, down from the previous minimum age of 17. This development is particularly significant as CDC data shows that 19% of new HIV diagnoses in the United States occur among young people aged 13-24, with only 6% of high school students ever being tested for HIV. Almost half of young people with HIV are unaware of their status.
The OraQuick® HIV Self-Test has been available to U.S. consumers since 2012. The test includes comprehensive educational materials and care information to help users make informed decisions regardless of results. This expansion aims to increase HIV testing accessibility among adolescents and support early connection to care for those who test positive.
OraSure Technologies (NASDAQ: OSUR) has announced the acquisition of Sherlock Biosciences, expanding its diagnostic test portfolio with advanced molecular diagnostics technology. The key acquisition focuses on Sherlock's molecular self-test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), which provides results in under 30 minutes using self-collected swabs.
The CT/NG test is currently in clinical studies with FDA submission expected by end of 2025. Upon regulatory approval, revenue contribution is anticipated to begin in 2026. The total addressable market for CT/NG testing exceeds $1.5 billion. The acquisition also includes Sherlock's pipeline of molecular tests and next-generation platforms, featuring Ambient Temperature Amplification and CRISPR-based technologies.
OraSure Technologies (NASDAQ: OSUR) has received a federal contract through the Rapid Response Partnership Vehicle (RRPV) to develop a Marburg Virus Disease (MVD) rapid antigen test. The initial contract is valued at $7.5 million over multiple years, with potential value up to $11 million. The funding from BARDA aims to achieve FDA 510(k) clearance for a single-use lateral flow immunoassay test designed to detect Marburg virus antigens in individuals with risk factors and symptoms. OraSure has previously worked with BARDA on the InteliSwab® COVID-19 Rapid Test and maintains an ongoing partnership for their OraQuick® Ebola Rapid Antigen Test.
OraSure Technologies (NASDAQ: OSUR) has announced its participation in the upcoming Stephens Annual Investment Conference on Wednesday, November 20. The company will engage in a Q&A session scheduled for 1 p.m. ET. Investors can access a live webcast and replay of the session through OraSure's investor relations webpage. The webcast recording will remain available for approximately 90 days following the event.